Lipid Metabolism: The significance of plasma proprotein convertase subtilisin kexin type 9 in the elucidation of complex lipid disorders

Current Opinion in Lipidology

Volumn 22, Issue 4, 2011, Pages 317-318

  Brouwers, Martijn C G J ^a   Van Greevenbroek, Marleen M J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; BIOLOGICAL MARKER; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMA PROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; LIPID METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ANIMALS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; LIPID METABOLISM; SERINE ENDOPEPTIDASES;

EID: 79960625066     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328348a5df     Document Type: Note

References (13)

1. Brouwers MC, de Graaf J, van Greevenbroek MM, et al. Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus. Curr Opin Lipidol 2010; 21:530-538.
2. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007; 18:304-309. (Pubitemid 46743055)
3. Chan DC, Lambert G, Barrett PH, et al. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism? Clin Chem 2009; 55:2049-2052.
4. Browning JD, Horton JD. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 2010; 51:3359-3363.
5. Persson L, Cao G, Stahle L, et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol 2010; 30:2666-2672.
6. Lambert G, Ancellin N, Charlton F, et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008; 54:1038-1045. (Pubitemid 351793411)
7. Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009; 94:2537-2543.
8. Baass A, Dubuc G, Tremblay M, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009; 55:1637-1645.
9. Brouwers MC, Troutt JS, Van Greevenbroek MM et al. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study. Atherosclerosis 2011. doi: 10.1016/j.athero sclerosis.2011.03.023
10. Howard BV, Abbott WG, Beltz WF, et al. Integrated study of low-density lipoprotein metabolism and very low density lipoprotein metabolism in noninsulin-dependent diabetes. Metabolism 1987; 36:870-877. (Pubitemid 17136045)
11. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Plasma low density lipoprotein transport kinetics in noninsulin-dependent diabetes mellitus. J Clin Invest 1983; 71:655-667. (Pubitemid 13160813)
12. Duvillard L, Florentin E, Lizard G, et al. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care 2003; 26:1540-1544. (Pubitemid 36929193)
13. Malmstrom R, Packard CJ, Caslake M, et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997; 40:454-462. (Pubitemid 27132616)